2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Phosphodiesterase (PDE)

Phosphodiesterase (PDE)

Phosphodiesterase (PDE)

Related Products

PDF 4.17 MB

Phosphodiesterase (PDE) is any enzyme that breaks a phosphodiester bond. Usually, people speaking of phosphodiesterase are referring to cyclic nucleotide phosphodiesterases, which have great clinical significance and are described below. However, there are many other families of phosphodiesterases, including phospholipases C and D, autotaxin, sphingomyelin phosphodiesterase, DNases, RNases, and restriction endonucleases, as well as numerous less-well-characterized small-molecule phosphodiesterases. The cyclic nucleotide phosphodiesterases comprise a group of enzymes that degrade the phosphodiester bond in the second messenger molecules cAMP and cGMP. They regulate the localization, duration, and amplitude of cyclic nucleotide signaling within subcellular domains. PDEs are therefore important regulators ofsignal transduction mediated by these second messenger molecules.

Phosphodiesterase (PDE) Isoform Specific Products:

Phosphodiesterase (PDE) Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-W011336
    PDE5-IN-7
    		Inhibitor 99.59%
    PDE5-IN-7 (compound 8) is a selective phosphodiesterase 5 (PDE 5) inhibitor with an IC50 value of 5 nM, while an IC50 of 300 nM for PDE 1.
    PDE5-IN-7
  • HY-104028A
    BAY 73-6691 racemate
    		Inhibitor 99.86%
    BAY 73-6691 racemate is a phosphodiesterase 9 inhibitor extracted from patent WO 2017070293 A1.
    BAY 73-6691 racemate
  • HY-133712
    Yonkenafil
    		Inhibitor 99.52%
    Yonkenafil (Tunodafil), a novel phosphodiesterase 5 (PDE5) inhibitor, is effective in reducing cerebral infarction, neurological deficits, edema, and neuronal damage in the infarcted area. Yonkenafil may improve cognitive function by modulating neurogenesis and has a potential therapeutic effect on Alzheimer's disease.
    Yonkenafil
  • HY-19672
    Lirimilast
    		Inhibitor 98.69%
    Lirimilast (BAY 19-8004) is a potent, selective and orally active phosphodiesterase-4 (PDE4) inhibitor with an IC50 value of 49 nM. Lirimilast can be used for the treatment of asthma or chronic obstructive pulmonary disease (COPD). Lirimilast has potently anti-inflammatory properties.
    Lirimilast
  • HY-401913
    endo CNTinh-03
    		Inhibitor 99.96%
    Endo CNTinh-03 is inhibitor for the elevation of cAMP and cGMP induced by agonist, such as G protein-coupled receptors, adenylate cyclase, and guanylate cyclase (IC50 is 4 μM). Endo CNTinh-03 inhibits cholera toxin- and Escherichia coli (STa) toxin- induced CFTR chloride current, ameliorates secretory diarrhea in mouse models, and prevents cyst growth in polycystic kidney disease model.
    endo CNTinh-03
  • HY-100164
    SDZ-MKS 492
    		Inhibitor 99.77%
    SDZ-MKS 492 (MKS 492) is a selective inhibitor of cyclic GMP-inhibited phosphodiesterase (type III PDE). SDZ-MKS 492 inhibits antigen- or platelet activating factor (PAF)-induced bronchoconstriction and allergic reactions in guinea pigs and rats.
    SDZ-MKS 492
  • HY-114672
    MBCQ
    		Inhibitor 99.80%
    MBCQ is a potent and selective cGMP-specific phosphodiesterase (PDE V; PDE5) inhibitor with an IC50 of 19 nM. MBCQ lacks inhibitory activity toward other PDE isozymes (all IC50s>100 μM). MBCQ dilates coronary arteries via specific inhibition of cGMP-PDE.
    MBCQ
  • HY-90009S
    Tadalafil-d3
    		Inhibitor 99.40%
    Tadalafil-d3 is the deuterium labeled Nortadalafil. Nortadalafil is demethyl Tadalafil, which is a PDE5 inhibitor, currently marketed in pill form for treating erectile dysfunction (ED) under the name Cialis; and under the name Adcirca for the treatment of pulmonary arterial hypertension.
    Tadalafil-d<sub>3</sub>
  • HY-117604
    THPP-1
    		Inhibitor 98.75%
    THPP-1, a SGC chemical probe, is a potent and orally bioavailable phosphodiesterase 10A (PDE10A) inhibitor, with Ki values of 1 nM and 1.3 nM for human and rat PDE10A, respectively. THPP-1 has excellent pharmacokinetic properties in preclinical species.
    THPP-1
  • HY-143469
    NPP1-IN-1
    		Inhibitor 99.56%
    NPP1-IN-1 is a potent NPP inhibitor with IC50s of 0.15 μM and 40 μM for NPP1 and NPP3, respectively.
    NPP1-IN-1
  • HY-100650
    Carbodenafil
    		Inhibitor 99.63%
    Carbodenafil is a Sildenafil (UK-92480) related compound found in health foods. Sildenafil is a potent phosphodiesterase type 5 (PDE5) inhibitor with an IC50 of 5.22 nM.
    Carbodenafil
  • HY-100530B
    Sp-cAMPS
    		Inhibitor
    Sp-cAMPS, a cAMP analog, is potent activator of cAMP-dependent PKA I and PKA II. Sp-cAMPS is also a potent, competitive phosphodiesterase (PDE3A) inhibitor with a Ki of 47.6 µM. Sp-cAMPS binds the PDE10 GAF domain with an EC50 of 40 μM.
    Sp-cAMPS
  • HY-I0636
    (R)-Apremilast
    		Control 99.99%
    (R)-Apremilast ((R)-CC-10004) is a enantiomer of Apremilast.
    (R)-Apremilast
  • HY-116100A
    HA155
    		Inhibitor 98.00%
    HA-155 is a potent and selective autotaxin (ATX) inhibitor with an IC50 of 5.7 nM.
    HA155
  • HY-112555
    PDE7-IN-2
    		Inhibitor ≥99.0%
    PDE7-IN-2 (compound 2) is a potent PDE7 (phosphodiesterase 7) inhibitor with IC50 value of 2.1 µM. PDE7-IN-2 has the potential for the research of parkinson’s disease.
    PDE7-IN-2
  • HY-18078
    PQ-10
    		Inhibitor 99.77%
    PQ-10 is a potent inhibitor of Phosphodiesterase 10A (PDE10A) with IC50 andED50 of 4.6 nM and 13 mg/kg, respectively. PQ-10 induces patterns of brain glucose metabolism which can be a potential translational biomarker. PQ-10 has the potential for researching psychiatric disorders like schizophrenia.
    PQ-10
  • HY-11070
    MK-0952
    		Inhibitor 99.71%
    MK-0952 is a selective and orally active PDE4 inhibitor, with an IC50 of 0.53 nM. MK-0952 has the potential for Alzheimer’s disease study.
    MK-0952
  • HY-N2913
    Ayanin
    		Inhibitor 98.18%
    Ayanin is a bioflavonoid isolated from Psychotria serpens. Ayanin is a non-selective phosphodiesterase1-4 inhibitor and can be used for the study of respiratory disease,such as allergic asthma et al.
    Ayanin
  • HY-136350B
    (S)-BRD9500
    		Control 99.67%
    (S)-BRD9500 is the isomer of BRD9500 (HY-136350), and can be used as an experimental control. BRD9500 is an orally active phosphodiesterases 3 (PDE3) inhibitor with IC50s of 10 and 27 nM for PDE3A and PDE3B, respectively. Antitumor activity.
    (S)-BRD9500
  • HY-143254
    Enpp-1-IN-10
    		Inhibitor 98.64%
    Enpp-1-IN-10 (compound 1) is a potent Ecto-nucleotide pyrophosphatase/phosphodiesterases 1 (ENPP1) inhibitor with an Ki value of 3.866 μM. Enpp-1-IN-10 can be used for researching anticancer.
    Enpp-1-IN-10
Cat. No. Product Name / Synonyms Application Reactivity
Phosphodiesterase (PDE) Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.